APO Research, Inc.
Talk to an analyst

APO RESEARCH · REPORT

Canine Cancer Screening

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Canine Cancer Screening Market Outlook and Growth Opportunities 2026

Report ID 17408513045 June 2026194 pages

Choose your research edition.

Industry ResearchCanine Cancer Screening Industry Research Report 2026121 pages · $2,950 USDIndustry Growth & TrendsGlobal Canine Cancer Screening Industry Growth and Trends Forecast to 2032104 pages · $3,450 USDMarket StructureGlobal Canine Cancer Screening Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032194 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Canine Cancer Screening Market Outlook and Growth Opportunities 2026194 pages · $4,250 USDMarket Analysis & ForecastGlobal Canine Cancer Screening Market Analysis and Forecast 2026-2032237 pages · $4,950 USD

Market perspective

The global Canine Cancer Screening market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Canine Cancer Screening is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Canine Cancer Screening is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Canine Cancer Screening is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Canine Cancer Screening market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Canine Cancer Screening market include IDEXX, Mars Pedtcare, Zoetis, PetDx, Molecular Diagnostics (MDxHealth), Biomérieux SA, OncoK9, Antech Diagnostics and VolitionRx Limited, among others. In 2025, the top three vendors together accounted for approximately % of global market revenue.

This report provides an overview of the global Canine Cancer Screening market in terms of revenue and gross margin, analyzing global market trends using historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Canine Cancer Screening and market revenue by major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Canine Cancer Screening revenue, market share, and industry ranking for the main companies for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

Across the 2021-2026 period, the analysis compares revenue growth and profitability profiles by company, distinguishing participants with sustained expansion from those with more cyclical performance, and relates these patterns to differences in regional exposure, product portfolios, and application focus in the global Canine Cancer Screening market.

Canine Cancer Screening Segment by Company

IDEXX

Mars Pedtcare

Zoetis

PetDx

Molecular Diagnostics (MDxHealth)

Biomérieux SA

OncoK9

Antech Diagnostics

VolitionRx Limited

Oncotect

Heska Corporation

Canine Cancer Screening Segment by Type

Liquid Biopsy (Blood-Based Tests)

Tissue Biopsy

Genomic Testing

Biomarker Tests

Canine Cancer Screening Segment by Application

Veterinary Clinics

Veterinary Hospitals

Other

Canine Cancer Screening Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Colombia

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Canine Cancer Screening status and future forecast, involving, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the Canine Cancer Screening key companies, revenue, market share, and recent developments.

3. To split the Canine Cancer Screening breakdown data by regions, type, companies, and application.

4. To analyze the global and key regions Canine Cancer Screening market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Canine Cancer Screening significant trends, drivers, influence factors in global and regions.

6. To analyze Canine Cancer Screening competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Canine Cancer Screening market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Canine Cancer Screening and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Canine Cancer Screening.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size.

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Canine Cancer Screening industry.

Chapter 3: Detailed analysis of Canine Cancer Screening company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales value of Canine Cancer Screening in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of key country in the world.

Chapter 7: Sales value of Canine Cancer Screening in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.

Chapter 9: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Canine Cancer Screening Industry Trends Table 2. Canine Cancer Screening Industry Drivers Table 3. Canine Cancer Screening Industry Opportunities and Challenges Table 4. Canine Cancer Screening Industry Restraints Table 5. Global Canine Cancer Screening Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Canine Cancer Screening Revenue Share by Company (2021-2026) Table 7. Global Canine Cancer Screening Company Ranking, (2024-2026) & (US$ Million) Table 8. Global Canine Cancer Screening Key Company Manufacturing Base & Headquarters Table 9. Global Canine Cancer Screening Company, Product Type & Application Table 10. Global Canine Cancer Screening Company Establishment Date Table 11. Global Company Market Concentration Ratio (CR5 and HHI) Table 12. Global Canine Cancer Screening by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 13. Mergers & Acquisitions, Expansion Table 14. Significant Companies of Liquid Biopsy (Blood-Based Tests) Table 15. Significant Companies of Tissue Biopsy Table 16. Significant Companies of Genomic Testing Table 17. Significant Companies of Biomarker Tests Table 18. Global Canine Cancer Screening Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 19. Global Canine Cancer Screening Sales Value by Type (2021-2026) & (US$ Million) Table 20. Global Canine Cancer Screening Sales Value by Type (2027-2032) & (US$ Million) Table 21. Global Canine Cancer Screening Sales Value Share by Type (2021-2026) Table 22. Global Canine Cancer Screening Sales Value Share by Type (2027-2032) Table 23. Significant Companies of Veterinary Clinics Table 24. Significant Companies of Veterinary Hospitals Table 25. Significant Companies of Other Table 26. Global Canine Cancer Screening Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 27. Global Canine Cancer Screening Sales Value by Application (2021-2026) & (US$ Million) Table 28. Global Canine Cancer Screening Sales Value by Application (2027-2032) & (US$ Million) Table 29. Global Canine Cancer Screening Sales Value Share by Application (2021-2026) Table 30. Global Canine Cancer Screening Sales Value Share by Application (2027-2032) Table 31. Global Canine Cancer Screening Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 32. Global Canine Cancer Screening Sales Value by Region (2021-2026) & (US$ Million) Table 33. Global Canine Cancer Screening Sales Value Share by Region (2021-2026) Table 34. Global Canine Cancer Screening Sales Value by Region (2027-2032) & (US$ Million) Table 35. Global Canine Cancer Screening Sales Value Share by Region (2027-2032) Table 36. Global Canine Cancer Screening Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 37. Global Canine Cancer Screening Sales Value by Country (2021-2026) & (US$ Million) Table 38. Global Canine Cancer Screening Sales Value Market Share by Country (2021-2026) Table 39. Global Canine Cancer Screening Sales Value by Country (2027-2032) & (US$ Million) Table 40. Global Canine Cancer Screening Sales Value Market Share by Country (2027-2032) Table 41. IDEXX Company Information Table 42. IDEXX Business Overview Table 43. IDEXX Canine Cancer Screening Revenue (US$ Million) and Gross Margin (2021-2026) Table 44. IDEXX Canine Cancer Screening Product Portfolio Table 45. IDEXX Recent Development Table 46. Mars Pedtcare Company Information Table 47. Mars Pedtcare Business Overview Table 48. Mars Pedtcare Canine Cancer Screening Revenue (US$ Million) and Gross Margin (2021-2026) Table 49. Mars Pedtcare Canine Cancer Screening Product Portfolio Table 50. Mars Pedtcare Recent Development Table 51. Zoetis Company Information Table 52. Zoetis Business Overview Table 53. Zoetis Canine Cancer Screening Revenue (US$ Million) and Gross Margin (2021-2026) Table 54. Zoetis Canine Cancer Screening Product Portfolio Table 55. Zoetis Recent Development Table 56. PetDx Company Information Table 57. PetDx Business Overview Table 58. PetDx Canine Cancer Screening Revenue (US$ Million) and Gross Margin (2021-2026) Table 59. PetDx Canine Cancer Screening Product Portfolio Table 60. PetDx Recent Development Table 61. Molecular Diagnostics (MDxHealth) Company Information Table 62. Molecular Diagnostics (MDxHealth) Business Overview Table 63. Molecular Diagnostics (MDxHealth) Canine Cancer Screening Revenue (US$ Million) and Gross Margin (2021-2026) Table 64. Molecular Diagnostics (MDxHealth) Canine Cancer Screening Product Portfolio Table 65. Molecular Diagnostics (MDxHealth) Recent Development Table 66. Biomérieux SA Company Information Table 67. Biomérieux SA Business Overview Table 68. Biomérieux SA Canine Cancer Screening Revenue (US$ Million) and Gross Margin (2021-2026) Table 69. Biomérieux SA Canine Cancer Screening Product Portfolio Table 70. Biomérieux SA Recent Development Table 71. OncoK9 Company Information Table 72. OncoK9 Business Overview Table 73. OncoK9 Canine Cancer Screening Revenue (US$ Million) and Gross Margin (2021-2026) Table 74. OncoK9 Canine Cancer Screening Product Portfolio Table 75. OncoK9 Recent Development Table 76. Antech Diagnostics Company Information Table 77. Antech Diagnostics Business Overview Table 78. Antech Diagnostics Canine Cancer Screening Revenue (US$ Million) and Gross Margin (2021-2026) Table 79. Antech Diagnostics Canine Cancer Screening Product Portfolio Table 80. Antech Diagnostics Recent Development Table 81. VolitionRx Limited Company Information Table 82. VolitionRx Limited Business Overview Table 83. VolitionRx Limited Canine Cancer Screening Revenue (US$ Million) and Gross Margin (2021-2026) Table 84. VolitionRx Limited Canine Cancer Screening Product Portfolio Table 85. VolitionRx Limited Recent Development Table 86. Oncotect Company Information Table 87. Oncotect Business Overview Table 88. Oncotect Canine Cancer Screening Revenue (US$ Million) and Gross Margin (2021-2026) Table 89. Oncotect Canine Cancer Screening Product Portfolio Table 90. Oncotect Recent Development Table 91. Heska Corporation Company Information Table 92. Heska Corporation Business Overview Table 93. Heska Corporation Canine Cancer Screening Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 94. Heska Corporation Canine Cancer Screening Product Portfolio Table 95. Heska Corporation Recent Development Table 96. Research Programs/Design for This Report Table 97. Authors List of This Report Table 98. Secondary Sources Table 99. Primary Sources List of Figures Figure 1. Canine Cancer Screening Product Image Figure 2. Global Canine Cancer Screening Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Canine Cancer Screening Market Size (2021-2032) & (US$ Million) Figure 4. Global Canine Cancer Screening Company Revenue Ranking in 2025 (US$ Million) Figure 5. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 6. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 7. Liquid Biopsy (Blood-Based Tests) Image Figure 8. Tissue Biopsy Image Figure 9. Genomic Testing Image Figure 10. Biomarker Tests Image Figure 11. Global Canine Cancer Screening Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 12. Global Canine Cancer Screening Sales Value Share 2021 VS 2025 VS 2032 Figure 13. Global Canine Cancer Screening Sales Value Share by Type (2021-2032) Figure 14. Veterinary Clinics Image Figure 15. Veterinary Hospitals Image Figure 16. Other Image Figure 17. Global Canine Cancer Screening Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 18. Global Canine Cancer Screening Sales Value Share 2021 VS 2025 VS 2032 Figure 19. Global Canine Cancer Screening Sales Value Share by Application (2021-2032) Figure 20. Global Canine Cancer Screening Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 21. Global Canine Cancer Screening Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 22. North America Canine Cancer Screening Sales Value (2021-2032) & (US$ Million) Figure 23. North America Canine Cancer Screening Sales Value Share by Country (%), 2025 VS 2032 Figure 24. Europe Canine Cancer Screening Sales Value (2021-2032) & (US$ Million) Figure 25. Europe Canine Cancer Screening Sales Value Share by Country (%), 2025 VS 2032 Figure 26. Asia-Pacific Canine Cancer Screening Sales Value (2021-2032) & (US$ Million) Figure 27. Asia-Pacific Canine Cancer Screening Sales Value Share by Country (%), 2025 VS 2032 Figure 28. South America Canine Cancer Screening Sales Value (2021-2032) & (US$ Million) Figure 29. South America Canine Cancer Screening Sales Value Share by Country (%), 2025 VS 2032 Figure 30. Middle East & Africa Canine Cancer Screening Sales Value (2021-2032) & (US$ Million) Figure 31. Middle East & Africa Canine Cancer Screening Sales Value Share by Country (%), 2025 VS 2032 Figure 32. USA Canine Cancer Screening Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 33. USA Canine Cancer Screening Sales Value Share by Type, 2025 VS 2032 & (%) Figure 34. USA Canine Cancer Screening Sales Value Share by Application, 2025 VS 2032 & (%) Figure 35. Canada Canine Cancer Screening Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 36. Canada Canine Cancer Screening Sales Value Share by Type, 2025 VS 2032 & (%) Figure 37. Canada Canine Cancer Screening Sales Value Share by Application, 2025 VS 2032 & (%) Figure 38. Mexico Canine Cancer Screening Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 39. Mexico Canine Cancer Screening Sales Value Share by Type, 2025 VS 2032 & (%) Figure 40. Mexico Canine Cancer Screening Sales Value Share by Application, 2025 VS 2032 & (%) Figure 41. Germany Canine Cancer Screening Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 42. Germany Canine Cancer Screening Sales Value Share by Type, 2025 VS 2032 & (%) Figure 43. Germany Canine Cancer Screening Sales Value Share by Application, 2025 VS 2032 & (%) Figure 44. France Canine Cancer Screening Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 45. France Canine Cancer Screening Sales Value Share by Type, 2025 VS 2032 & (%) Figure 46. France Canine Cancer Screening Sales Value Share by Application, 2025 VS 2032 & (%) Figure 47. U.K. Canine Cancer Screening Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 48. U.K. Canine Cancer Screening Sales Value Share by Type, 2025 VS 2032 & (%) Figure 49. U.K. Canine Cancer Screening Sales Value Share by Application, 2025 VS 2032 & (%) Figure 50. Italy Canine Cancer Screening Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 51. Italy Canine Cancer Screening Sales Value Share by Type, 2025 VS 2032 & (%) Figure 52. Italy Canine Cancer Screening Sales Value Share by Application, 2025 VS 2032 & (%) Figure 53. Spain Canine Cancer Screening Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 54. Spain Canine Cancer Screening Sales Value Share by Type, 2025 VS 2032 & (%) Figure 55. Spain Canine Cancer Screening Sales Value Share by Application, 2025 VS 2032 & (%) Figure 56. Russia Canine Cancer Screening Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 57. Russia Canine Cancer Screening Sales Value Share by Type, 2025 VS 2032 & (%) Figure 58. Russia Canine Cancer Screening Sales Value Share by Application, 2025 VS 2032 & (%) Figure 59. Netherlands Canine Cancer Screening Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 60. Netherlands Canine Cancer Screening Sales Value Share by Type, 2025 VS 2032 & (%) Figure 61. Netherlands Canine Cancer Screening Sales Value Share by Application, 2025 VS 2032 & (%) Figure 62. Nordic Countries Canine Cancer Screening Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 63. Nordic Countries Canine Cancer Screening Sales Value Share by Type, 2025 VS 2032 & (%) Figure 64. Nordic Countries Canine Cancer Screening Sales Value Share by Application, 2025 VS 2032 & (%) Figure 65. China Canine Cancer Screening Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 66. China Canine Cancer Screening Sales Value Share by Type, 2025 VS 2032 & (%) Figure 67. China Canine Cancer Screening Sales Value Share by Application, 2025 VS 2032 & (%) Figure 68. Japan Canine Cancer Screening Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 69. Japan Canine Cancer Screening Sales Value Share by Type, 2025 VS 2032 & (%) Figure 70. Japan Canine Cancer Screening Sales Value Share by Application, 2025 VS 2032 & (%) Figure 71. South Korea Canine Cancer Screening Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 72. South Korea Canine Cancer Screening Sales Value Share by Type, 2025 VS 2032 & (%) Figure 73. South Korea Canine Cancer Screening Sales Value Share by Application, 2025 VS 2032 & (%) Figure 74. India Canine Cancer Screening Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 75. India Canine Cancer Screening Sales Value Share by Type, 2025 VS 2032 & (%) Figure 76. India Canine Cancer Screening Sales Value Share by Application, 2025 VS 2032 & (%) Figure 77. Australia Canine Cancer Screening Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 78. Australia Canine Cancer Screening Sales Value Share by Type, 2025 VS 2032 & (%) Figure 79. Australia Canine Cancer Screening Sales Value Share by Application, 2025 VS 2032 & (%) Figure 80. Southeast Asia Canine Cancer Screening Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 81. Southeast Asia Canine Cancer Screening Sales Value Share by Type, 2025 VS 2032 & (%) Figure 82. Southeast Asia Canine Cancer Screening Sales Value Share by Application, 2025 VS 2032 & (%) Figure 83. Brazil Canine Cancer Screening Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 84. Brazil Canine Cancer Screening Sales Value Share by Type, 2025 VS 2032 & (%) Figure 85. Brazil Canine Cancer Screening Sales Value Share by Application, 2025 VS 2032 & (%) Figure 86. Argentina Canine Cancer Screening Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 87. Argentina Canine Cancer Screening Sales Value Share by Type, 2025 VS 2032 & (%) Figure 88. Argentina Canine Cancer Screening Sales Value Share by Application, 2025 VS 2032 & (%) Figure 89. Chile Canine Cancer Screening Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 90. Chile Canine Cancer Screening Sales Value Share by Type, 2025 VS 2032 & (%) Figure 91. Chile Canine Cancer Screening Sales Value Share by Application, 2025 VS 2032 & (%) Figure 92. Colombia Canine Cancer Screening Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 93. Colombia Canine Cancer Screening Sales Value Share by Type, 2025 VS 2032 & (%) Figure 94. Colombia Canine Cancer Screening Sales Value Share by Application, 2025 VS 2032 & (%) Figure 95. Peru Canine Cancer Screening Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 96. Peru Canine Cancer Screening Sales Value Share by Type, 2025 VS 2032 & (%) Figure 97. Peru Canine Cancer Screening Sales Value Share by Application, 2025 VS 2032 & (%) Figure 98. Saudi Arabia Canine Cancer Screening Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 99. Saudi Arabia Canine Cancer Screening Sales Value Share by Type, 2025 VS 2032 & (%) Figure 100. Saudi Arabia Canine Cancer Screening Sales Value Share by Application, 2025 VS 2032 & (%) Figure 101. Israel Canine Cancer Screening Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 102. Israel Canine Cancer Screening Sales Value Share by Type, 2025 VS 2032 & (%) Figure 103. Israel Canine Cancer Screening Sales Value Share by Application, 2025 VS 2032 & (%) Figure 104. UAE Canine Cancer Screening Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 105. UAE Canine Cancer Screening Sales Value Share by Type, 2025 VS 2032 & (%) Figure 106. UAE Canine Cancer Screening Sales Value Share by Application, 2025 VS 2032 & (%) Figure 107. Turkey Canine Cancer Screening Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 108. Turkey Canine Cancer Screening Sales Value Share by Type, 2025 VS 2032 & (%) Figure 109. Turkey Canine Cancer Screening Sales Value Share by Application, 2025 VS 2032 & (%) Figure 110. Iran Canine Cancer Screening Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 111. Iran Canine Cancer Screening Sales Value Share by Type, 2025 VS 2032 & (%) Figure 112. Iran Canine Cancer Screening Sales Value Share by Application, 2025 VS 2032 & (%) Figure 113. Egypt Canine Cancer Screening Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 114. Egypt Canine Cancer Screening Sales Value Share by Type, 2025 VS 2032 & (%) Figure 115. Egypt Canine Cancer Screening Sales Value Share by Application, 2025 VS 2032 & (%) Figure 116. Years Considered Figure 117. Research Process Figure 118. Key Executives Interviewed

Scope & coverage.

Types
  • Liquid Biopsy (Blood-Based Tests)
  • Tissue Biopsy
  • Genomic Testing
  • Biomarker Tests
Applications
  • Veterinary Clinics
  • Veterinary Hospitals
  • Other
Companies covered
  • IDEXX
  • Mars Pedtcare
  • Zoetis
  • PetDx
  • Molecular Diagnostics (MDxHealth)
  • Biomérieux SA
  • OncoK9
  • Antech Diagnostics
  • VolitionRx Limited
  • Oncotect
  • Heska Corporation

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Canine Cancer Screening Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Canine Cancer Screening Market Size (2021-2032)
  4. 1.4 Assumptions and Limitations
  5. 1.5 Study Goals and Objectives
2 Canine Cancer Screening Market Dynamics
  1. 2.1 Canine Cancer Screening Industry Trends
  2. 2.2 Canine Cancer Screening Industry Drivers
  3. 2.3 Canine Cancer Screening Industry Opportunities and Challenges
  4. 2.4 Canine Cancer Screening Industry Restraints
3 Canine Cancer Screening Market by Company
  1. 3.1 Global Canine Cancer Screening Company Revenue Ranking in 2025
  2. 3.2 Global Canine Cancer Screening Revenue by Company (2021-2026)
  3. 3.3 Global Canine Cancer Screening Company Ranking (2024-2026)
  4. 3.4 Global Canine Cancer Screening Company Manufacturing Base and Headquarters
  5. 3.5 Global Canine Cancer Screening Company Product Type and Application
  6. 3.6 Global Canine Cancer Screening Company Establishment Date
  7. 3.7 Market Competitive Analysis
  8. 3.7.1 Global Canine Cancer Screening Market Concentration Ratio (CR5 and HHI)
  9. 3.7.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  10. 3.7.3 2025 Canine Cancer Screening Tier 1, Tier 2, and Tier 3 Companies
  11. 3.8 Mergers and Acquisitions Expansion
4 Canine Cancer Screening Market by Type
  1. 4.1 Canine Cancer Screening Type Introduction
  2. 4.1.1 Liquid Biopsy (Blood-Based Tests)
  3. 4.1.2 Tissue Biopsy
  4. 4.1.3 Genomic Testing
  5. 4.1.4 Biomarker Tests
  6. 4.2 Global Canine Cancer Screening Sales Value by Type
  7. 4.2.1 Global Canine Cancer Screening Sales Value by Type (2021 VS 2025 VS 2032)
  8. 4.2.2 Global Canine Cancer Screening Sales Value by Type (2021-2032)
  9. 4.2.3 Global Canine Cancer Screening Sales Value Share by Type (2021-2032)
5 Canine Cancer Screening Market by Application
  1. 5.1 Canine Cancer Screening Application Introduction
  2. 5.1.1 Veterinary Clinics
  3. 5.1.2 Veterinary Hospitals
  4. 5.1.3 Other
  5. 5.2 Global Canine Cancer Screening Sales Value by Application
  6. 5.2.1 Global Canine Cancer Screening Sales Value by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Canine Cancer Screening Sales Value by Application (2021-2032)
  8. 5.2.3 Global Canine Cancer Screening Sales Value Share by Application (2021-2032)
6 Canine Cancer Screening Regional Value Analysis
  1. 6.1 Global Canine Cancer Screening Sales Value by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Canine Cancer Screening Sales Value by Region (2021-2032)
  3. 6.2.1 Global Canine Cancer Screening Sales Value by Region: 2021-2026
  4. 6.2.2 Global Canine Cancer Screening Sales Value by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Canine Cancer Screening Sales Value (2021-2032)
  7. 6.3.2 North America Canine Cancer Screening Sales Value Share by Country, 2025 VS 2032
  8. 6.4 Europe
  9. 6.4.1 Europe Canine Cancer Screening Sales Value (2021-2032)
  10. 6.4.2 Europe Canine Cancer Screening Sales Value Share by Country, 2025 VS 2032
  11. 6.5 Asia-Pacific
  12. 6.5.1 Asia-Pacific Canine Cancer Screening Sales Value (2021-2032)
  13. 6.5.2 Asia-Pacific Canine Cancer Screening Sales Value Share by Country, 2025 VS 2032
  14. 6.6 South America
  15. 6.6.1 South America Canine Cancer Screening Sales Value (2021-2032)
  16. 6.6.2 South America Canine Cancer Screening Sales Value Share by Country, 2025 VS 2032
  17. 6.7 Middle East & Africa
  18. 6.7.1 Middle East & Africa Canine Cancer Screening Sales Value (2021-2032)
  19. 6.7.2 Middle East & Africa Canine Cancer Screening Sales Value Share by Country, 2025 VS 2032
7 Canine Cancer Screening Country-level Value Analysis
  1. 7.1 Global Canine Cancer Screening Sales Value by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Canine Cancer Screening Sales Value by Country (2021-2032)
  3. 7.2.1 Global Canine Cancer Screening Sales Value by Country (2021-2026)
  4. 7.2.2 Global Canine Cancer Screening Sales Value by Country (2027-2032)
  5. 7.3 USA
  6. 7.3.1 USA Canine Cancer Screening Sales Value Growth Rate (2021-2032)
  7. 7.3.2 USA Canine Cancer Screening Sales Value Share by Type, 2025 VS 2032
  8. 7.3.3 USA Canine Cancer Screening Sales Value Share by Application, 2025 VS 2032
  9. 7.4 Canada
  10. 7.4.1 Canada Canine Cancer Screening Sales Value Growth Rate (2021-2032)
  11. 7.4.2 Canada Canine Cancer Screening Sales Value Share by Type, 2025 VS 2032
  12. 7.4.3 Canada Canine Cancer Screening Sales Value Share by Application, 2025 VS 2032
  13. 7.5 Mexico
  14. 7.5.1 Mexico Canine Cancer Screening Sales Value Growth Rate (2021-2032)
  15. 7.5.2 Mexico Canine Cancer Screening Sales Value Share by Type, 2025 VS 2032
  16. 7.5.3 Mexico Canine Cancer Screening Sales Value Share by Application, 2025 VS 2032
  17. 7.6 Germany
  18. 7.6.1 Germany Canine Cancer Screening Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Germany Canine Cancer Screening Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Germany Canine Cancer Screening Sales Value Share by Application, 2025 VS 2032
  21. 7.7 France
  22. 7.7.1 France Canine Cancer Screening Sales Value Growth Rate (2021-2032)
  23. 7.7.2 France Canine Cancer Screening Sales Value Share by Type, 2025 VS 2032
  24. 7.7.3 France Canine Cancer Screening Sales Value Share by Application, 2025 VS 2032
  25. 7.8 U.K.
  26. 7.8.1 U.K. Canine Cancer Screening Sales Value Growth Rate (2021-2032)
  27. 7.8.2 U.K. Canine Cancer Screening Sales Value Share by Type, 2025 VS 2032
  28. 7.8.3 U.K. Canine Cancer Screening Sales Value Share by Application, 2025 VS 2032
  29. 7.9 Italy
  30. 7.9.1 Italy Canine Cancer Screening Sales Value Growth Rate (2021-2032)
  31. 7.9.2 Italy Canine Cancer Screening Sales Value Share by Type, 2025 VS 2032
  32. 7.9.3 Italy Canine Cancer Screening Sales Value Share by Application, 2025 VS 2032
  33. 7.10 Spain
  34. 7.10.1 Spain Canine Cancer Screening Sales Value Growth Rate (2021-2032)
  35. 7.10.2 Spain Canine Cancer Screening Sales Value Share by Type, 2025 VS 2032
  36. 7.10.3 Spain Canine Cancer Screening Sales Value Share by Application, 2025 VS 2032
  37. 7.11 Russia
  38. 7.11.1 Russia Canine Cancer Screening Sales Value Growth Rate (2021-2032)
  39. 7.11.2 Russia Canine Cancer Screening Sales Value Share by Type, 2025 VS 2032
  40. 7.11.3 Russia Canine Cancer Screening Sales Value Share by Application, 2025 VS 2032
  41. 7.12 Netherlands
  42. 7.12.1 Netherlands Canine Cancer Screening Sales Value Growth Rate (2021-2032)
  43. 7.12.2 Netherlands Canine Cancer Screening Sales Value Share by Type, 2025 VS 2032
  44. 7.12.3 Netherlands Canine Cancer Screening Sales Value Share by Application, 2025 VS 2032
  45. 7.13 Nordic Countries
  46. 7.13.1 Nordic Countries Canine Cancer Screening Sales Value Growth Rate (2021-2032)
  47. 7.13.2 Nordic Countries Canine Cancer Screening Sales Value Share by Type, 2025 VS 2032
  48. 7.13.3 Nordic Countries Canine Cancer Screening Sales Value Share by Application, 2025 VS 2032
  49. 7.14 China
  50. 7.14.1 China Canine Cancer Screening Sales Value Growth Rate (2021-2032)
  51. 7.14.2 China Canine Cancer Screening Sales Value Share by Type, 2025 VS 2032
  52. 7.14.3 China Canine Cancer Screening Sales Value Share by Application, 2025 VS 2032
  53. 7.15 Japan
  54. 7.15.1 Japan Canine Cancer Screening Sales Value Growth Rate (2021-2032)
  55. 7.15.2 Japan Canine Cancer Screening Sales Value Share by Type, 2025 VS 2032
  56. 7.15.3 Japan Canine Cancer Screening Sales Value Share by Application, 2025 VS 2032
  57. 7.16 South Korea
  58. 7.16.1 South Korea Canine Cancer Screening Sales Value Growth Rate (2021-2032)
  59. 7.16.2 South Korea Canine Cancer Screening Sales Value Share by Type, 2025 VS 2032
  60. 7.16.3 South Korea Canine Cancer Screening Sales Value Share by Application, 2025 VS 2032
  61. 7.17 India
  62. 7.17.1 India Canine Cancer Screening Sales Value Growth Rate (2021-2032)
  63. 7.17.2 India Canine Cancer Screening Sales Value Share by Type, 2025 VS 2032
  64. 7.17.3 India Canine Cancer Screening Sales Value Share by Application, 2025 VS 2032
  65. 7.18 Australia
  66. 7.18.1 Australia Canine Cancer Screening Sales Value Growth Rate (2021-2032)
  67. 7.18.2 Australia Canine Cancer Screening Sales Value Share by Type, 2025 VS 2032
  68. 7.18.3 Australia Canine Cancer Screening Sales Value Share by Application, 2025 VS 2032
  69. 7.19 Southeast Asia
  70. 7.19.1 Southeast Asia Canine Cancer Screening Sales Value Growth Rate (2021-2032)
  71. 7.19.2 Southeast Asia Canine Cancer Screening Sales Value Share by Type, 2025 VS 2032
  72. 7.19.3 Southeast Asia Canine Cancer Screening Sales Value Share by Application, 2025 VS 2032
  73. 7.20 Brazil
  74. 7.20.1 Brazil Canine Cancer Screening Sales Value Growth Rate (2021-2032)
  75. 7.20.2 Brazil Canine Cancer Screening Sales Value Share by Type, 2025 VS 2032
  76. 7.20.3 Brazil Canine Cancer Screening Sales Value Share by Application, 2025 VS 2032
  77. 7.21 Argentina
  78. 7.21.1 Argentina Canine Cancer Screening Sales Value Growth Rate (2021-2032)
  79. 7.21.2 Argentina Canine Cancer Screening Sales Value Share by Type, 2025 VS 2032
  80. 7.21.3 Argentina Canine Cancer Screening Sales Value Share by Application, 2025 VS 2032
  81. 7.22 Chile
  82. 7.22.1 Chile Canine Cancer Screening Sales Value Growth Rate (2021-2032)
  83. 7.22.2 Chile Canine Cancer Screening Sales Value Share by Type, 2025 VS 2032
  84. 7.22.3 Chile Canine Cancer Screening Sales Value Share by Application, 2025 VS 2032
  85. 7.23 Colombia
  86. 7.23.1 Colombia Canine Cancer Screening Sales Value Growth Rate (2021-2032)
  87. 7.23.2 Colombia Canine Cancer Screening Sales Value Share by Type, 2025 VS 2032
  88. 7.23.3 Colombia Canine Cancer Screening Sales Value Share by Application, 2025 VS 2032
  89. 7.24 Peru
  90. 7.24.1 Peru Canine Cancer Screening Sales Value Growth Rate (2021-2032)
  91. 7.24.2 Peru Canine Cancer Screening Sales Value Share by Type, 2025 VS 2032
  92. 7.24.3 Peru Canine Cancer Screening Sales Value Share by Application, 2025 VS 2032
  93. 7.25 Saudi Arabia
  94. 7.25.1 Saudi Arabia Canine Cancer Screening Sales Value Growth Rate (2021-2032)
  95. 7.25.2 Saudi Arabia Canine Cancer Screening Sales Value Share by Type, 2025 VS 2032
  96. 7.25.3 Saudi Arabia Canine Cancer Screening Sales Value Share by Application, 2025 VS 2032
  97. 7.26 Israel
  98. 7.26.1 Israel Canine Cancer Screening Sales Value Growth Rate (2021-2032)
  99. 7.26.2 Israel Canine Cancer Screening Sales Value Share by Type, 2025 VS 2032
  100. 7.26.3 Israel Canine Cancer Screening Sales Value Share by Application, 2025 VS 2032
  101. 7.27 UAE
  102. 7.27.1 UAE Canine Cancer Screening Sales Value Growth Rate (2021-2032)
  103. 7.27.2 UAE Canine Cancer Screening Sales Value Share by Type, 2025 VS 2032
  104. 7.27.3 UAE Canine Cancer Screening Sales Value Share by Application, 2025 VS 2032
  105. 7.28 Turkey
  106. 7.28.1 Turkey Canine Cancer Screening Sales Value Growth Rate (2021-2032)
  107. 7.28.2 Turkey Canine Cancer Screening Sales Value Share by Type, 2025 VS 2032
  108. 7.28.3 Turkey Canine Cancer Screening Sales Value Share by Application, 2025 VS 2032
  109. 7.29 Iran
  110. 7.29.1 Iran Canine Cancer Screening Sales Value Growth Rate (2021-2032)
  111. 7.29.2 Iran Canine Cancer Screening Sales Value Share by Type, 2025 VS 2032
  112. 7.29.3 Iran Canine Cancer Screening Sales Value Share by Application, 2025 VS 2032
  113. 7.30 Egypt
  114. 7.30.1 Egypt Canine Cancer Screening Sales Value Growth Rate (2021-2032)
  115. 7.30.2 Egypt Canine Cancer Screening Sales Value Share by Type, 2025 VS 2032
  116. 7.30.3 Egypt Canine Cancer Screening Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 IDEXX
  2. 8.1.1 IDEXX Company Information
  3. 8.1.2 IDEXX Business Overview
  4. 8.1.3 IDEXX Canine Cancer Screening Revenue and Gross Margin (2021-2026)
  5. 8.1.4 IDEXX Canine Cancer Screening Product Portfolio
  6. 8.1.5 IDEXX Recent Developments
  7. 8.2 Mars Pedtcare
  8. 8.2.1 Mars Pedtcare Company Information
  9. 8.2.2 Mars Pedtcare Business Overview
  10. 8.2.3 Mars Pedtcare Canine Cancer Screening Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Mars Pedtcare Canine Cancer Screening Product Portfolio
  12. 8.2.5 Mars Pedtcare Recent Developments
  13. 8.3 Zoetis
  14. 8.3.1 Zoetis Company Information
  15. 8.3.2 Zoetis Business Overview
  16. 8.3.3 Zoetis Canine Cancer Screening Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Zoetis Canine Cancer Screening Product Portfolio
  18. 8.3.5 Zoetis Recent Developments
  19. 8.4 PetDx
  20. 8.4.1 PetDx Company Information
  21. 8.4.2 PetDx Business Overview
  22. 8.4.3 PetDx Canine Cancer Screening Revenue and Gross Margin (2021-2026)
  23. 8.4.4 PetDx Canine Cancer Screening Product Portfolio
  24. 8.4.5 PetDx Recent Developments
  25. 8.5 Molecular Diagnostics (MDxHealth)
  26. 8.5.1 Molecular Diagnostics (MDxHealth) Company Information
  27. 8.5.2 Molecular Diagnostics (MDxHealth) Business Overview
  28. 8.5.3 Molecular Diagnostics (MDxHealth) Canine Cancer Screening Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Molecular Diagnostics (MDxHealth) Canine Cancer Screening Product Portfolio
  30. 8.5.5 Molecular Diagnostics (MDxHealth) Recent Developments
  31. 8.6 Biomérieux SA
  32. 8.6.1 Biomérieux SA Company Information
  33. 8.6.2 Biomérieux SA Business Overview
  34. 8.6.3 Biomérieux SA Canine Cancer Screening Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Biomérieux SA Canine Cancer Screening Product Portfolio
  36. 8.6.5 Biomérieux SA Recent Developments
  37. 8.7 OncoK9
  38. 8.7.1 OncoK9 Company Information
  39. 8.7.2 OncoK9 Business Overview
  40. 8.7.3 OncoK9 Canine Cancer Screening Revenue and Gross Margin (2021-2026)
  41. 8.7.4 OncoK9 Canine Cancer Screening Product Portfolio
  42. 8.7.5 OncoK9 Recent Developments
  43. 8.8 Antech Diagnostics
  44. 8.8.1 Antech Diagnostics Company Information
  45. 8.8.2 Antech Diagnostics Business Overview
  46. 8.8.3 Antech Diagnostics Canine Cancer Screening Revenue and Gross Margin (2021-2026)
  47. 8.8.4 Antech Diagnostics Canine Cancer Screening Product Portfolio
  48. 8.8.5 Antech Diagnostics Recent Developments
  49. 8.9 VolitionRx Limited
  50. 8.9.1 VolitionRx Limited Company Information
  51. 8.9.2 VolitionRx Limited Business Overview
  52. 8.9.3 VolitionRx Limited Canine Cancer Screening Revenue and Gross Margin (2021-2026)
  53. 8.9.4 VolitionRx Limited Canine Cancer Screening Product Portfolio
  54. 8.9.5 VolitionRx Limited Recent Developments
  55. 8.10 Oncotect
  56. 8.10.1 Oncotect Company Information
  57. 8.10.2 Oncotect Business Overview
  58. 8.10.3 Oncotect Canine Cancer Screening Revenue and Gross Margin (2021-2026)
  59. 8.10.4 Oncotect Canine Cancer Screening Product Portfolio
  60. 8.10.5 Oncotect Recent Developments
  61. 8.11 Heska Corporation
  62. 8.11.1 Heska Corporation Company Information
  63. 8.11.2 Heska Corporation Business Overview
  64. 8.11.3 Heska Corporation Canine Cancer Screening Revenue and Gross Margin (2021-2026)
  65. 8.11.4 Heska Corporation Canine Cancer Screening Product Portfolio
  66. 8.11.5 Heska Corporation Recent Developments
9 Concluding Insights
    10 Appendix
    1. 10.1 Reasons for Doing This Study
    2. 10.2 Research Methodology
    3. 10.3 Research Process
    4. 10.4 Authors List of This Report
    5. 10.5 Data Source
    6. 10.5.1 Secondary Sources
    7. 10.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research, Inc.
    Talk to an analyst